China Traditional Chinese Medicine Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	5.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

China Traditional Chinese Medicine Holdings CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Yang	Chairman	less than a year	Veri yok	Veri yok
Hongjian Li	President & Executive Director	less than a year	Veri yok	Veri yok
Lixin Shen	VP & Financial Director	3.3yrs	Veri yok	Veri yok
Dongji Zhao	VP, Joint Company Secretary	7.4yrs	CN¥1.56m	Veri yok
Sau Mei Ng	Joint Company Secretary	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: 570 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jun Yang	Chairman	less than a year	Veri yok	Veri yok
Hongjian Li	President & Executive Director	less than a year	Veri yok	Veri yok
Rong Xie	Independent Non-Executive Director	11.8yrs	CN¥279.00k	Veri yok
Ling Qin	Independent Non-Executive Director	5.8yrs	CN¥279.00k	Veri yok
Tze Shan Yu	Independent Non-Executive Director	11.1yrs	CN¥279.00k	Veri yok
Weidong Li	Independent Non-Executive Director	5.8yrs	CN¥279.00k	Veri yok
Wenming Yang	Non-Executive Director	6yrs	CN¥2.60m	Veri yok
Binghua Yang	Non-Executive Director	6yrs	Veri yok	Veri yok
Xueren Cheng	Non-Executive Director	2.8yrs	CN¥2.49m	Veri yok
Ru Li	Non-Executive Director	5.8yrs	Veri yok	Veri yok
Qingxin Meng	Non-Executive Director	2.1yrs	Veri yok	Veri yok
Kan Wang	Non-Executive Director	6yrs	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 570 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 23:07
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

China Traditional Chinese Medicine Holdings Co. Limited 25 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ling Zhang	BNP Paribas Securities (Asia)
Yue-Kwong Lui	BOCOM International Securities Limited
Helena Qiu	CCB International Securities Limited

China Traditional Chinese Medicine Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

China Traditional Chinese Medicine Holdings Co. Limited Announces Executive, Board and Committee Appointments

China Traditional Chinese Medicine Holdings Co. Limited Announces Board Changes

China Traditional Chinese Medicine Holdings Co. Limited, Annual General Meeting, Jun 14, 2024

Less than half of directors are independent

China Traditional Chinese Medicine Holdings Co. Limited Announces Resignation of Kui Kaipin as Non-Executive Director, with Effect from August 29, 2023

China Traditional Chinese Medicine Holdings Co. Limited Announces Management Changes

Recent updates

Sinopharm Common Wealth Company Limited cancelled the acquisition of 67.54% stake in China Traditional Chinese Medicine Holdings Co. Limited (SEHK:570) from China Asset Management Co. Ltd., China Asset Management (Hong Kong) Limited and others.

Sinopharm Common Wealth Company Limited cancelled the acquisition of 67.54% stake in China Traditional Chinese Medicine Holdings Co. Limited (SEHK:570) from China Asset Management Co. Ltd., China Asset Management (Hong Kong) Limited and others.

First half 2024 earnings released: EPS: CN¥0.042 (vs CN¥0.12 in 1H 2023)

China Traditional Chinese Medicine Holdings Co. Limited Announces Executive, Board and Committee Appointments

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.042 (vs CN¥0.12 in 1H 2023)

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 15%

China Traditional Chinese Medicine Holdings Co. Limited Announces Board Changes

China Traditional Chinese Medicine Holdings Co. Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.15 in FY 2022)

Less than half of directors are independent

Investor sentiment improves as stock rises 15%

China Traditional Chinese Medicine Holdings Co. Limited Provides Preliminary Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 17%

First half 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.082 in 1H 2022)

China Traditional Chinese Medicine Holdings Co. Limited Announces Resignation of Kui Kaipin as Non-Executive Director, with Effect from August 29, 2023

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2023 Results on Aug 29, 2023

China Traditional Chinese Medicine Holdings Co. Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023

China Traditional Chinese Medicine Holdings Co. Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.052 per share at 1.3% yield

China Traditional Chinese Medicine Holdings Co. Limited Proposes Final Dividend for the Year Ended 31 December 2022

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.38 in FY 2021)

China Traditional Chinese Medicine Holdings Co. Limited Provides Earning Guidance for the Year Ended 31 December 2022

Investor sentiment improved over the past week

China Traditional Chinese Medicine Holdings Co. Limited Announces Management Changes

Less than half of directors are independent

China Traditional Chinese Medicine Holdings Co. Limited Do Not Recommend the Payment of an Interim Dividend for the Six Months Ended 30 June 2022

First half 2022 earnings released: EPS: CN¥0.082 (vs CN¥0.18 in 1H 2021)

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

China Traditional Chinese Medicine Holdings Co. Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

China Traditional Chinese Medicine Holdings Co. Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 29 July 2022

Upcoming dividend of HK$0.074 per share

China Traditional Chinese Medicine Holdings Co. Limited Recommends Final Dividend for the Year Ended 31 December 2021

China Traditional Chinese Medicine Holdings Co. Limited Recommends Final Dividend for the Year Ended 31 December 2021

China Traditional Chinese Medicine Holdings Co. Limited Announces Executive Changes

Full year 2021 earnings released: EPS: CN¥0.38 (vs CN¥0.33 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.38 (vs CN¥0.33 in FY 2020)

Investor sentiment improved over the past week

Now 20% undervalued

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.18 (vs CN¥0.14 in 1H 2020)

Upcoming dividend of HK$0.067 per share

First half 2021 earnings released: EPS CN¥0.18 (vs CN¥0.14 in 1H 2020)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.32 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.32 in FY 2019)

China Traditional Chinese Medicine Holdings Co. Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

New 90-day high: HK$4.77

New 90-day high: HK$4.05

New 90-day high: HK$3.84

New 90-day high: HK$3.65

New 90-day low: HK$3.14

New 90-day low: HK$3.15

First half earnings released

China Traditional Chinese Medicine Holdings Co. Limited Not Recommends Interim Dividend for the Six Months Ended 30 June 2020

New 90-day low - HK$3.31

China Traditional Chinese Medicine Holdings Co. Limited to Report First Half, 2020 Results on Aug 21, 2020

First half earnings released

China Traditional Chinese Medicine Holdings Co. Limited Recommends No Interim Dividend for the Six Months Ended 30 June 2020

CEO

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi